Skip to main content

Table 2 Risk of death from breast cancer in association with Menacalc

From: Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer

Combined Cohort 1 and 2 (n = 608; 231)*

Variable

 

cHR (95% CI)

P-value

Age

   
 

<50

1.00

0.0738

 

>50

1.316 (0.97 to 1.78)

 

Tumor size

  
 

<2 cm

1.00

<0.0001

 

2 to 5 cm

2.127 (1.57 to 2.88)

 

Nuclear grade

  
 

low

1.00

 
 

high

1.250 (0.93 to 1.68)

0.0397

 

ND

2.414 (1.10 to 5.32)

 

Nodal status

  
 

Positive

2.161 (1.60 to 2.92)

<0.0001

 

Negative

1.00

 

ER

   
 

Positive

0.755 (0.57 to 1.00)

0.0549

 

Negative

1.00

 

PR

   
 

Positive

0.899 (0.68 to 1.19)

0.4602

 

Negative

1.00

 

Her2

   
 

Positive

1.360 (0.96 to 1.93)

0.0834

 

Negative

1.00

 

Menacalc

   
 

1 to 3 Q

1.00

 
 

4 Q

1.597 (1.20 to 2.13)

0.0015

Menacalc

continuous

1.211 (1.08 to 1.36)

0.0016

  1. The P-values are shown for a 20-year follow-up and bold numbers indicate statistically significant P-value.
  2. *The number of patients in each cohort is shown followed by the number of patient deaths due to disease.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us